Mark Hillman Hillman Capital Management
Mark Hillman is associated with Hillman Capital Management, a firm focused on fundamental equity research and long-term portfolio management. The firm’s public filings are followed by investors interested in actively managed, research-driven U.S. equity exposure. Hillman’s process emphasizes business analysis and valuation discipline rather than short-term trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$6.43M |
| 2 |
Western Union
WU
|
+$6.22M |
| 3 |
Conagra Brands
CAG
|
+$3.51M |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$815K |
| 5 |
Air Products & Chemicals
APD
|
+$570K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$7.59M |
| 2 |
Simon Property Group
SPG
|
+$888K |
| 3 |
Microsoft
MSFT
|
+$850K |
| 4 |
Marriott International
MAR
|
+$591K |
| 5 |
AB InBev
BUD
|
+$529K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.86% |
| 2 | Communication Services | 12.83% |
| 3 | Industrials | 11.71% |
| 4 | Energy | 11.58% |
| 5 | Consumer Staples | 11.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
iShares MSCI Emerging Markets ETF
EEM
$30.7B
| $12K | ﹤0.01% |
+250
| New | +$12.6K |
|
52
iShares Russell Mid-Cap Value ETF
IWS
$15.9B
| $5K | ﹤0.01% |
+44
| New | +$5.25K |
|
53
iShares Russell Mid-Cap Growth ETF
IWP
$20.7B
| $4K | ﹤0.01% |
+33
| New | +$3.85K |
|
54
iShares Russell 2000 Value ETF
IWN
$14.6B
| $3K | ﹤0.01% |
+17
| New | +$2.83K |
|
55
iShares Core US Aggregate Bond ETF
AGG
$138B
| – | – |
-281
| Closed | -$32K |
|
56
iShares Core S&P Small-Cap ETF
IJR
$111B
| – | – |
-424
| Closed | -$46K |
|
|
57
Marriott International
MAR
$92.9B
| – | – |
-3,990
| Closed | -$591K |
|
|
58
Pfizer
PFE
$160B
| – | – |
-176,532
| Closed | -$7.59M |
|
Similar funds
Mark Hillman's Q4 2021 Portfolio in Review
As of Q4 2021, Mark Hillman held 58 positions worth $291M, up 2.1% from $285M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Mark Hillman's Q4 2021 filing shows 7 new, 5 increased, 42 reduced and 4 closed positions. Its largest new stake was Air Products & Chemicals: 1,943 shares worth $591K. The largest sale was Pfizer, an estimated $7.59M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 20% a quarter earlier, followed by Communication Services and Industrials.
- Mark Hillman's largest Q4 2021 buy was Air Products & Chemicals: 1,943 shares worth $591K.
- Mark Hillman added most to Zimmer Biomet in Q4 2021, an estimated $6.43M increase.
- Mark Hillman's biggest Q4 2021 reduction was Simon Property Group, cutting an estimated $888K.
- Mark Hillman fully exited Pfizer in Q4 2021, selling an estimated $7.59M.
- Mark Hillman's ten largest holdings make up 36% of its $291M portfolio in Q4 2021.
- Mark Hillman opened 7 new positions and closed 4 in Q4 2021.
- Mark Hillman's portfolio value rose 2.1% quarter-over-quarter to $291M.
Based on Hillman Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.